Qiagen Buys AmniSure for Noninvasive Fetal Membrane Rupture Assay
Marketed test kit will generate an estimated $12 million in sales over the remainder of 2012.
Qiagen has bought AmniSure International for the Boston-based firm’s marketed AmniSure® assay for detecting rupture of fetal membranes (ROM) in pregnancy. About 30% of pregnant women are currently assessed for ROM, a condition in which amniotic fluid leaks from the amniotic sac prematurely, commonly leading to maternal and neonatal infections, as well as premature birth.
The point-of-need AmniSure test comprises a one-step, minimally invasive test strip that can detect amniotic fluid in vaginal discharge within minutes. “This accurate diagnostic test contributes significant value in the management of pregnancy and adds to Qiagen’s portfolio of tests, in particular for the ob/gyn market,” comments Peer Schatz, CEO.
AmniSure will operate as a wholly owned subsidiary of Qiagen. Acquisition of the business will add about $12 million to Qiagen’s sales sheet in 2012, and an expected $24 million in 2013.